Telesis Bio 5/8/2026 Earnings Report

Telesis Bio EPS Results

• Actual EPS: N/A
• Consensus EPS: -$6.39
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Telesis Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.53 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Telesis Bio Announcement Details

• Date: 5/8/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Telesis Bio (NASDAQ:TBIO) is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications.

The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants. These agents are being evaluated both as monotherapies in solid tumors and in combination with checkpoint inhibitors, with the goal of converting immunologically “cold” tumors into “hot” ones that are more likely to respond to treatment. In parallel, Telesis Bio is exploring the use of its PRR agonists as adjuvants in therapeutic and prophylactic vaccines, aiming to improve antigen-specific immune activation.

Founded in 2015 and headquartered in South San Francisco, California, Telesis Bio collaborates with leading academic institutions and biotechnology partners to accelerate its research and development efforts. The company is led by an experienced management team with expertise in immunology, molecular biology, and clinical development. Telesis Bio continues to expand its platform through strategic partnerships and preclinical studies, with the objective of delivering next-generation immunotherapies to patients in the United States and globally.